SCHEMBL2779689

SCHEMBL2779689

N#CC(c1ccccc1F)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
ACHE P22303 2/20 0.46
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 3/20 0.43
HPGD P15428 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CYP2A13 Q16696 1/20 0.41
DPP4 P27487 1/20 0.40
MAPT P10636 3/20 0.38
HTT P42858 2/20 0.38
ALOX15 P16050 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15797576 0.89 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL2782859 0.82 SLC6A2 (0.52) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL3472406 0.82 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL2781199 0.81 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL18274473 0.80 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL11460899 0.79 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL16796793 0.79 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL2781893 0.77 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL14593353 0.77 MC4R (0.47) ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10
SCHEMBL17240237 0.76 CYP2A13 (0.44) ALDH1A1KDM4EHSD17B10HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718774-B2 Indole carboxamide derivatives as P2X7 receptor antagonist IDORSIA PHARMACEUTICALS LTD (CH) 2017-08-01 US disclosed
EP-2931717-B1 INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2016-12-07 EP disclosed
US-20150322008-A1 INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST ACTELION PHARMACEUTICALS LTD (CH) 2015-11-12 US disclosed
US-7795256-B2 Thieno-pyridinone derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2010-09-14 US disclosed
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors CELLTECH R&D LIMITED (GB) 2007-04-05 US disclosed
EP-1680429-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS Celltech R & D Limited (GB) 2006-07-19 EP disclosed
WO-2005042540-A1 THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2005-05-12 WO disclosed
US-4112095-A 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents AMERICAN CYANAMID COMPANY (US) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322008-A1 INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST P2RX3, P2RX7, P2RX1 ALDH1A1 1594/4885SMN1; SMN2 4608/4885ACHE 1018/4885
US-20070078131-A1 Thieno-pyridinone derivatives as kinase inhibitors MAP3K6, MAP4K2, MAP3K15 ALDH1A1 2586/4885SMN1; SMN2 3314/4885ACHE 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.